Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury




Linnéa Lagerstedt, Leire Azurmendi, Olli Tenovuo, Ari J. Katila, Riikka S. K. Takala, Kaj Blennow, Virginia F. J. Newcombe, Henna-Riikka Maanpää, Jussi Tallus, Iftakher Hossain, Mark van Gils, David K. Menon, Peter J. Hutchinson, Henrik Zetterberg, Jussi P. Posti, Jean-Charles Sanchez

PublisherFRONTIERS MEDIA SA

2020

Frontiers in Neurology

FRONTIERS IN NEUROLOGY

FRONT NEUROL

ARTN 376

11

9

1664-2295

1664-2295

DOIhttps://doi.org/10.3389/fneur.2020.00376

https://research.utu.fi/converis/portal/detail/Publication/48900330



Background:Patients with traumatic brain injury (TBI) exhibit a variable and unpredictable outcome. The proteins interleukin 10 (IL-10) and heart fatty acid-binding protein (H-FABP) have shown predictive values for the presence of intracranial lesions. Aim:To evaluate the individual and combined outcome prediction ability of IL-10 and H-FABP, and to compare them to the more studied proteins S100 beta, glial fibrillary acidic protein (GFAP), and neurofilament light (NF-L), both with and without clinical predictors. Methods:Blood samples from patients with acute TBI (all severities) were collected 6 months post injury using the Glasgow Outcome Scale Extended (GOSE) score, dichotomizing patients into: (i) those with favorable (GOSE >= 5)/unfavorable outcome (GOSE <= 4) and complete (GOSE = 8)/incomplete (GOSE <= 7) recovery, and (ii) patients with mild TBI (mTBI) and patients with TBIs of all severities. Results:When sensitivity was set at 95-100%, the proteins' individual specificities remained low. H-FABP showed the best specificity (%) and sensitivity (100%) in predicting complete recovery in patients with mTBI. IL-10 had the best specificity (50%) and sensitivity (96%) in identifying patients with favorable outcome in patients with TBIs of all severities. When individual proteins were combined with clinical parameters, a model including H-FABP, NF-L, and ISS yielded a specificity of 56% and a sensitivity of 96% in predicting complete recovery in patients with mTBI. In predicting favorable outcome, a model consisting IL-10, age, and TBI severity reached a specificity of 80% and a sensitivity of 96% in patients with TBIs of all severities. Conclusion:Combining novel TBI biomarkers H-FABP and IL-10 with GFAP, NF-L and S100 beta and clinical parameters improves outcome prediction models in TBI.

Last updated on 2024-26-11 at 13:27